Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials (Q34647375)

3 August 2017

0 references

Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials (English)

1 reference

3 August 2017

0 references

0 references

1 reference

M D Ferrari

1 reference

3 August 2017

R B Lipton

1 reference

3 August 2017

P J Goadsby

1 reference

3 August 2017

K I Roon

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 November 2001

1 reference

3 August 2017

1 reference

inferred from page(s)

published in

The Lancet

1 reference

3 August 2017

volume

358

1 reference

3 August 2017

issue

9294

1 reference

3 August 2017

page(s)

1668-1675

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

3 August 2017

1 reference

7 January 2021

Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Ergotamine in the acute treatment of migraine: a review and European consensus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Serotonin and migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

The pharmacology of headache

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

The Mode of Action of Sumatriptan is Vascular? A Debate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Serotonin 5-HT1B/1D Receptor Agonists in Migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Methodology of clinical trials of sumatriptan in migraine and cluster headache

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Guidelines for controlled trials of drugs in migraine: second edition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Efficacy and adverse events of subcutaneous, oral, and intranasal sumatriptan used for migraine treatment: a systematic review based on number needed to treat

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Absorption of effervescent aspirin during migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Determinants of patient satisfaction with migraine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Risk factors for headache recurrence after sumatriptan: a study in 366 migraine patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Oral sumatriptan: effect of a second dose, and incidence and treatment of headache recurrences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Rizatriptan 022 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

1 reference

7 January 2021

Headache after frequent use of serotonin agonists zolmitriptan and naratriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

How to assess and compare drugs in the management of migraine: success rates in terms of response and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

A general parametric approach to the meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Using numerical results from systematic reviews in clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Within-patient consistency of response of rizatriptan for treating migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Coronary side-effect potential of current and prospective antimigraine drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Characteristics and Determinants of Sumatriptan-Associated Chest Pain

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

Treatment of migraine attacks with sumatriptan. The Subcutaneous Sumatriptan International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906711-3

7 January 2021

10.1016/S0140-6736(01)06711-3

Identifiers

DOI

1 reference

3 August 2017

1 reference